Neil Everett Martin, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Prostatic Neoplasms | 79 | 2024 | 11101 | 3.150 |
Why?
|
Prostatectomy | 24 | 2024 | 1786 | 1.320 |
Why?
|
Androgen Antagonists | 21 | 2024 | 1412 | 1.290 |
Why?
|
Testicular Neoplasms | 10 | 2024 | 806 | 1.150 |
Why?
|
Prostate-Specific Antigen | 19 | 2023 | 2463 | 1.110 |
Why?
|
Brachytherapy | 17 | 2021 | 1220 | 0.990 |
Why?
|
Radiosurgery | 6 | 2023 | 1330 | 0.930 |
Why?
|
Prostate | 12 | 2024 | 1765 | 0.810 |
Why?
|
Radiation Oncology | 5 | 2024 | 572 | 0.800 |
Why?
|
Kallikreins | 3 | 2018 | 219 | 0.700 |
Why?
|
Health Status Indicators | 2 | 2015 | 969 | 0.660 |
Why?
|
Hearing Loss | 6 | 2024 | 785 | 0.650 |
Why?
|
Tinnitus | 4 | 2023 | 197 | 0.540 |
Why?
|
Patient-Centered Care | 4 | 2024 | 1444 | 0.520 |
Why?
|
Tosyl Compounds | 2 | 2014 | 115 | 0.500 |
Why?
|
Quality Indicators, Health Care | 2 | 2015 | 1805 | 0.480 |
Why?
|
Gastrointestinal Diseases | 1 | 2023 | 1206 | 0.470 |
Why?
|
SEER Program | 18 | 2019 | 1444 | 0.450 |
Why?
|
Antineoplastic Agents, Hormonal | 5 | 2017 | 1536 | 0.450 |
Why?
|
Critical Pathways | 1 | 2017 | 476 | 0.450 |
Why?
|
RNA, Neoplasm | 2 | 2015 | 749 | 0.430 |
Why?
|
Medical Oncology | 2 | 2015 | 2346 | 0.420 |
Why?
|
Anilides | 2 | 2014 | 413 | 0.410 |
Why?
|
Flutamide | 1 | 2012 | 95 | 0.390 |
Why?
|
Health Status | 2 | 2015 | 4091 | 0.390 |
Why?
|
Radiotherapy | 5 | 2019 | 1502 | 0.360 |
Why?
|
Nitriles | 2 | 2014 | 980 | 0.350 |
Why?
|
Quality of Health Care | 3 | 2020 | 4310 | 0.330 |
Why?
|
Language | 1 | 2019 | 1557 | 0.330 |
Why?
|
Complementary Therapies | 1 | 2013 | 487 | 0.320 |
Why?
|
Male | 95 | 2024 | 364719 | 0.310 |
Why?
|
Cisplatin | 6 | 2024 | 1660 | 0.310 |
Why?
|
Adenocarcinoma | 6 | 2019 | 6395 | 0.310 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 3 | 2024 | 498 | 0.290 |
Why?
|
Neuralgia | 2 | 2024 | 621 | 0.290 |
Why?
|
Survivors | 3 | 2024 | 2381 | 0.280 |
Why?
|
Bone Neoplasms | 3 | 2017 | 2565 | 0.270 |
Why?
|
Health Personnel | 1 | 2020 | 3385 | 0.260 |
Why?
|
Lymphoma, Non-Hodgkin | 2 | 2013 | 1375 | 0.260 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2015 | 2885 | 0.250 |
Why?
|
Humans | 108 | 2024 | 768166 | 0.250 |
Why?
|
Neoplasm Staging | 17 | 2019 | 11244 | 0.250 |
Why?
|
Aged | 67 | 2024 | 171504 | 0.240 |
Why?
|
Patient Education as Topic | 1 | 2015 | 2337 | 0.240 |
Why?
|
Testosterone | 2 | 2014 | 2491 | 0.240 |
Why?
|
Cancer Care Facilities | 3 | 2017 | 427 | 0.240 |
Why?
|
Alkyl and Aryl Transferases | 1 | 2004 | 89 | 0.230 |
Why?
|
Healthcare Disparities | 6 | 2016 | 3415 | 0.210 |
Why?
|
Neoplasms, Second Primary | 4 | 2021 | 1061 | 0.210 |
Why?
|
Neoplasms | 8 | 2024 | 22371 | 0.210 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3115 | 0.200 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3238 | 0.200 |
Why?
|
Middle Aged | 58 | 2024 | 223492 | 0.200 |
Why?
|
Delivery of Health Care | 1 | 2020 | 5367 | 0.200 |
Why?
|
Travel | 2 | 2018 | 805 | 0.200 |
Why?
|
Health Behavior | 1 | 2013 | 2650 | 0.190 |
Why?
|
Tumor Burden | 3 | 2024 | 1906 | 0.190 |
Why?
|
Logistic Models | 12 | 2024 | 13290 | 0.190 |
Why?
|
Exercise | 2 | 2015 | 5955 | 0.180 |
Why?
|
Particle Accelerators | 1 | 2021 | 173 | 0.180 |
Why?
|
Salvage Therapy | 3 | 2017 | 1273 | 0.180 |
Why?
|
Proportional Hazards Models | 16 | 2020 | 12543 | 0.180 |
Why?
|
Early Detection of Cancer | 1 | 2015 | 3239 | 0.180 |
Why?
|
Marital Status | 4 | 2015 | 426 | 0.180 |
Why?
|
Watchful Waiting | 3 | 2019 | 492 | 0.170 |
Why?
|
Pandemics | 1 | 2020 | 8748 | 0.170 |
Why?
|
Palliative Care | 2 | 2017 | 3643 | 0.170 |
Why?
|
Databases, Factual | 10 | 2019 | 8080 | 0.160 |
Why?
|
Antineoplastic Agents | 6 | 2024 | 13676 | 0.160 |
Why?
|
PTEN Phosphohydrolase | 2 | 2015 | 1120 | 0.150 |
Why?
|
Anti-Anxiety Agents | 1 | 2021 | 405 | 0.150 |
Why?
|
Quality of Life | 4 | 2024 | 13490 | 0.150 |
Why?
|
Imidazoles | 1 | 2004 | 1169 | 0.150 |
Why?
|
Academic Medical Centers | 3 | 2017 | 2784 | 0.150 |
Why?
|
Neurotoxicity Syndromes | 1 | 2022 | 302 | 0.150 |
Why?
|
Divorce | 1 | 2018 | 78 | 0.150 |
Why?
|
Risk Assessment | 12 | 2020 | 24315 | 0.150 |
Why?
|
Anxiety | 2 | 2024 | 4672 | 0.150 |
Why?
|
Speech Perception | 1 | 2022 | 510 | 0.140 |
Why?
|
Fatigue | 1 | 2024 | 1557 | 0.140 |
Why?
|
Diet | 1 | 2015 | 8089 | 0.140 |
Why?
|
Organizational Case Studies | 1 | 2017 | 301 | 0.140 |
Why?
|
Risk Factors | 22 | 2024 | 74944 | 0.130 |
Why?
|
Radiation Injuries | 2 | 2014 | 1198 | 0.130 |
Why?
|
Magnetic Resonance Spectroscopy | 2 | 2023 | 3780 | 0.130 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2018 | 1791 | 0.130 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2022 | 716 | 0.130 |
Why?
|
Pancreatic Neoplasms | 2 | 2023 | 5446 | 0.130 |
Why?
|
Treatment Outcome | 19 | 2017 | 65371 | 0.130 |
Why?
|
Aged, 80 and over | 22 | 2019 | 59629 | 0.120 |
Why?
|
Combined Modality Therapy | 6 | 2019 | 8542 | 0.120 |
Why?
|
Quality Improvement | 2 | 2024 | 3857 | 0.120 |
Why?
|
Radiotherapy, Intensity-Modulated | 1 | 2021 | 798 | 0.120 |
Why?
|
Disease-Free Survival | 5 | 2017 | 6847 | 0.120 |
Why?
|
Immunohistochemistry | 5 | 2015 | 11095 | 0.120 |
Why?
|
Smad4 Protein | 1 | 2015 | 193 | 0.120 |
Why?
|
United States | 26 | 2019 | 73039 | 0.120 |
Why?
|
Vasectomy | 1 | 2014 | 52 | 0.110 |
Why?
|
Prognosis | 12 | 2024 | 30010 | 0.110 |
Why?
|
Time Factors | 11 | 2018 | 40218 | 0.110 |
Why?
|
Paraffin Embedding | 1 | 2015 | 307 | 0.110 |
Why?
|
Tissue Fixation | 1 | 2015 | 246 | 0.110 |
Why?
|
Osteopontin | 1 | 2015 | 306 | 0.110 |
Why?
|
Formaldehyde | 1 | 2015 | 362 | 0.110 |
Why?
|
Cyclin D1 | 1 | 2015 | 453 | 0.110 |
Why?
|
Gene Expression Profiling | 4 | 2017 | 9538 | 0.110 |
Why?
|
Depression | 2 | 2024 | 8230 | 0.100 |
Why?
|
Neoplasm Recurrence, Local | 7 | 2016 | 9419 | 0.100 |
Why?
|
Anus Neoplasms | 1 | 2016 | 336 | 0.100 |
Why?
|
Socioeconomic Factors | 6 | 2017 | 7852 | 0.100 |
Why?
|
Nephrectomy | 1 | 2018 | 930 | 0.100 |
Why?
|
Follow-Up Studies | 15 | 2019 | 39348 | 0.100 |
Why?
|
Urology | 1 | 2017 | 384 | 0.100 |
Why?
|
Telephone | 1 | 2016 | 630 | 0.100 |
Why?
|
Rectum | 2 | 2014 | 900 | 0.100 |
Why?
|
Medically Uninsured | 2 | 2016 | 840 | 0.100 |
Why?
|
Health Status Disparities | 2 | 2014 | 1885 | 0.100 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 905 | 0.100 |
Why?
|
Superoxide Dismutase | 1 | 2015 | 596 | 0.100 |
Why?
|
Seminoma | 1 | 2013 | 136 | 0.100 |
Why?
|
Organs at Risk | 1 | 2014 | 367 | 0.100 |
Why?
|
Stromal Cells | 1 | 2017 | 1336 | 0.100 |
Why?
|
Prospective Studies | 8 | 2024 | 54926 | 0.100 |
Why?
|
Survival Rate | 7 | 2016 | 12840 | 0.090 |
Why?
|
Income | 3 | 2014 | 1878 | 0.090 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2014 | 410 | 0.090 |
Why?
|
Survival Analysis | 6 | 2018 | 10101 | 0.090 |
Why?
|
Community Health Services | 1 | 2016 | 659 | 0.090 |
Why?
|
Radiotherapy, Conformal | 1 | 2014 | 549 | 0.090 |
Why?
|
Endoribonucleases | 1 | 2013 | 231 | 0.090 |
Why?
|
Receptor, IGF Type 1 | 1 | 2013 | 384 | 0.090 |
Why?
|
User-Computer Interface | 1 | 2017 | 1407 | 0.090 |
Why?
|
Treatment Refusal | 1 | 2014 | 433 | 0.090 |
Why?
|
Cohort Studies | 11 | 2020 | 41754 | 0.090 |
Why?
|
Geriatric Assessment | 2 | 2017 | 1422 | 0.090 |
Why?
|
Delphi Technique | 1 | 2014 | 891 | 0.090 |
Why?
|
Insulin Resistance | 1 | 2024 | 3986 | 0.090 |
Why?
|
beta Carotene | 1 | 2011 | 523 | 0.090 |
Why?
|
Predictive Value of Tests | 6 | 2018 | 15454 | 0.090 |
Why?
|
Medical Informatics | 1 | 2017 | 743 | 0.080 |
Why?
|
Disease Progression | 6 | 2017 | 13671 | 0.080 |
Why?
|
Artificial Intelligence | 1 | 2024 | 2665 | 0.080 |
Why?
|
Gene Fusion | 1 | 2012 | 356 | 0.080 |
Why?
|
Retrospective Studies | 17 | 2024 | 81762 | 0.080 |
Why?
|
Enzyme Activation | 1 | 2015 | 3590 | 0.080 |
Why?
|
Edema | 1 | 2013 | 765 | 0.080 |
Why?
|
Multivariate Analysis | 6 | 2019 | 12077 | 0.080 |
Why?
|
Ambulatory Care | 1 | 2020 | 2783 | 0.080 |
Why?
|
Guidelines as Topic | 1 | 2015 | 1397 | 0.080 |
Why?
|
Sexual Behavior | 1 | 2019 | 2197 | 0.080 |
Why?
|
Consensus | 2 | 2019 | 3212 | 0.080 |
Why?
|
Antidepressive Agents | 1 | 2021 | 2913 | 0.080 |
Why?
|
Gonadotropin-Releasing Hormone | 1 | 2014 | 1149 | 0.080 |
Why?
|
Hyperpigmentation | 1 | 2009 | 116 | 0.070 |
Why?
|
Cause of Death | 6 | 2018 | 3721 | 0.070 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2009 | 876 | 0.070 |
Why?
|
Adult | 20 | 2024 | 223646 | 0.070 |
Why?
|
Health Surveys | 1 | 2017 | 4057 | 0.070 |
Why?
|
Genetic Association Studies | 2 | 2015 | 2744 | 0.070 |
Why?
|
Serine Endopeptidases | 1 | 2012 | 1027 | 0.070 |
Why?
|
Cognition | 1 | 2024 | 7073 | 0.070 |
Why?
|
Myocardial Infarction | 3 | 2013 | 11519 | 0.070 |
Why?
|
Age Factors | 7 | 2018 | 18412 | 0.070 |
Why?
|
Radiotherapy Dosage | 3 | 2023 | 2916 | 0.070 |
Why?
|
Propensity Score | 3 | 2021 | 1969 | 0.070 |
Why?
|
Odds Ratio | 5 | 2017 | 9669 | 0.060 |
Why?
|
Insurance Coverage | 2 | 2014 | 1946 | 0.060 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2013 | 1613 | 0.060 |
Why?
|
Diabetes Mellitus | 1 | 2024 | 5889 | 0.060 |
Why?
|
Epithelial Cells | 1 | 2017 | 3703 | 0.060 |
Why?
|
Alopecia | 1 | 2009 | 416 | 0.060 |
Why?
|
Cost of Illness | 1 | 2015 | 1951 | 0.060 |
Why?
|
Vitamins | 1 | 2013 | 1638 | 0.060 |
Why?
|
Regression Analysis | 4 | 2016 | 6340 | 0.060 |
Why?
|
Farnesyltranstransferase | 1 | 2004 | 71 | 0.060 |
Why?
|
Incidence | 7 | 2015 | 21538 | 0.060 |
Why?
|
Weight Gain | 1 | 2014 | 2359 | 0.060 |
Why?
|
Urogenital System | 1 | 2023 | 88 | 0.050 |
Why?
|
Anti-Inflammatory Agents | 1 | 2013 | 1805 | 0.050 |
Why?
|
Patient Acceptance of Health Care | 1 | 2017 | 3231 | 0.050 |
Why?
|
Antioxidants | 1 | 2011 | 1673 | 0.050 |
Why?
|
Transcription, Genetic | 1 | 2017 | 7608 | 0.050 |
Why?
|
Risk | 4 | 2019 | 9613 | 0.050 |
Why?
|
Software | 1 | 2017 | 4478 | 0.050 |
Why?
|
Lymph Nodes | 1 | 2014 | 3474 | 0.050 |
Why?
|
Cost-Benefit Analysis | 1 | 2016 | 5536 | 0.050 |
Why?
|
Overweight | 1 | 2014 | 2448 | 0.050 |
Why?
|
Health Care Costs | 1 | 2016 | 3239 | 0.050 |
Why?
|
Trans-Activators | 1 | 2012 | 2857 | 0.050 |
Why?
|
Radiation Tolerance | 2 | 2016 | 476 | 0.050 |
Why?
|
Drug Therapy, Combination | 1 | 2012 | 6316 | 0.050 |
Why?
|
Insurance, Health | 1 | 2014 | 2517 | 0.050 |
Why?
|
Aspirin | 1 | 2013 | 3135 | 0.050 |
Why?
|
Coronary Artery Bypass | 1 | 2010 | 2191 | 0.050 |
Why?
|
Sensation Disorders | 1 | 2022 | 160 | 0.050 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2016 | 4058 | 0.050 |
Why?
|
Biopsy, Needle | 2 | 2017 | 1622 | 0.050 |
Why?
|
Carrier Proteins | 1 | 2014 | 4937 | 0.050 |
Why?
|
Health Services Accessibility | 1 | 2018 | 5520 | 0.040 |
Why?
|
Fiducial Markers | 1 | 2021 | 134 | 0.040 |
Why?
|
Coronary Disease | 1 | 2014 | 5919 | 0.040 |
Why?
|
RNA, Messenger | 1 | 2015 | 12800 | 0.040 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 11878 | 0.040 |
Why?
|
Confidence Intervals | 2 | 2015 | 2923 | 0.040 |
Why?
|
Electronic Health Records | 1 | 2017 | 4887 | 0.040 |
Why?
|
Physicians | 1 | 2017 | 4598 | 0.040 |
Why?
|
Infusions, Intravenous | 1 | 2004 | 2230 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 3 | 2023 | 36743 | 0.040 |
Why?
|
Disease Management | 2 | 2019 | 2536 | 0.040 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2013 | 3251 | 0.040 |
Why?
|
Ovarian Neoplasms | 1 | 2015 | 4916 | 0.040 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2017 | 3800 | 0.040 |
Why?
|
Pharmacogenetics | 1 | 2022 | 683 | 0.040 |
Why?
|
Speech | 1 | 2022 | 557 | 0.040 |
Why?
|
Obesity | 2 | 2024 | 13090 | 0.030 |
Why?
|
Organ Size | 2 | 2013 | 2267 | 0.030 |
Why?
|
Heart Failure | 2 | 2011 | 11879 | 0.030 |
Why?
|
Educational Status | 2 | 2014 | 2515 | 0.030 |
Why?
|
Marriage | 1 | 2018 | 351 | 0.030 |
Why?
|
Cryotherapy | 1 | 2017 | 164 | 0.030 |
Why?
|
Stents | 2 | 2023 | 3195 | 0.030 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2017 | 300 | 0.030 |
Why?
|
Data Display | 1 | 2016 | 174 | 0.030 |
Why?
|
Disabled Persons | 1 | 2024 | 1210 | 0.030 |
Why?
|
Body Composition | 1 | 2024 | 2462 | 0.030 |
Why?
|
Feasibility Studies | 2 | 2017 | 5315 | 0.030 |
Why?
|
Trypsin Inhibitor, Kazal Pancreatic | 1 | 2014 | 30 | 0.030 |
Why?
|
Goserelin | 1 | 2014 | 126 | 0.030 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2023 | 1679 | 0.030 |
Why?
|
Delayed Diagnosis | 1 | 2018 | 467 | 0.030 |
Why?
|
Minority Health | 1 | 2014 | 79 | 0.030 |
Why?
|
Diagnosis-Related Groups | 1 | 2015 | 445 | 0.030 |
Why?
|
Survival | 1 | 2013 | 160 | 0.030 |
Why?
|
Community Health Centers | 1 | 2017 | 469 | 0.030 |
Why?
|
Leuprolide | 1 | 2014 | 313 | 0.030 |
Why?
|
Epithelium | 1 | 2017 | 1607 | 0.030 |
Why?
|
Phantoms, Imaging | 1 | 2021 | 2512 | 0.030 |
Why?
|
Tissue Array Analysis | 1 | 2014 | 551 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2004 | 10760 | 0.020 |
Why?
|
Congresses as Topic | 1 | 2017 | 812 | 0.020 |
Why?
|
Signal Transduction | 1 | 2015 | 23645 | 0.020 |
Why?
|
Postoperative Complications | 1 | 2014 | 15832 | 0.020 |
Why?
|
Drug Prescriptions | 1 | 2021 | 1668 | 0.020 |
Why?
|
Demography | 1 | 2016 | 1641 | 0.020 |
Why?
|
Area Under Curve | 1 | 2015 | 1643 | 0.020 |
Why?
|
Urethra | 1 | 2013 | 406 | 0.020 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2015 | 879 | 0.020 |
Why?
|
Epidemiologic Methods | 1 | 2015 | 1328 | 0.020 |
Why?
|
Neoadjuvant Therapy | 2 | 2013 | 2907 | 0.020 |
Why?
|
Lymphoma, Mantle-Cell | 1 | 2013 | 240 | 0.020 |
Why?
|
Kidney Diseases | 1 | 2021 | 2100 | 0.020 |
Why?
|
Waist Circumference | 1 | 2013 | 935 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2020 | 2954 | 0.020 |
Why?
|
Iodine Radioisotopes | 1 | 2013 | 1034 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2017 | 8647 | 0.020 |
Why?
|
Phenotype | 2 | 2018 | 16726 | 0.020 |
Why?
|
Young Adult | 4 | 2021 | 60066 | 0.020 |
Why?
|
Self Report | 1 | 2021 | 3773 | 0.020 |
Why?
|
History, 21st Century | 1 | 2015 | 1573 | 0.020 |
Why?
|
Morbidity | 1 | 2015 | 1755 | 0.020 |
Why?
|
Muscle, Skeletal | 1 | 2024 | 4978 | 0.020 |
Why?
|
Sex Distribution | 1 | 2014 | 2278 | 0.020 |
Why?
|
Research Design | 1 | 2024 | 6211 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2017 | 3556 | 0.020 |
Why?
|
Female | 9 | 2016 | 397192 | 0.020 |
Why?
|
Lymphoma, Follicular | 1 | 2013 | 460 | 0.020 |
Why?
|
Liver | 1 | 2024 | 7577 | 0.020 |
Why?
|
Evolution, Molecular | 1 | 2016 | 1896 | 0.020 |
Why?
|
Radiometry | 1 | 2013 | 818 | 0.020 |
Why?
|
Angioplasty | 1 | 2010 | 355 | 0.020 |
Why?
|
Mortality | 1 | 2019 | 2911 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2004 | 17140 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2015 | 10399 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 2015 | 2914 | 0.020 |
Why?
|
History, 20th Century | 1 | 2015 | 2766 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2015 | 3620 | 0.020 |
Why?
|
Diagnostic Imaging | 1 | 2021 | 3533 | 0.020 |
Why?
|
Gene Rearrangement | 1 | 2012 | 1146 | 0.020 |
Why?
|
Bone and Bones | 1 | 2017 | 2589 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2017 | 6526 | 0.020 |
Why?
|
Physical Examination | 1 | 2013 | 1263 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2017 | 4912 | 0.020 |
Why?
|
Treatment Failure | 1 | 2013 | 2661 | 0.020 |
Why?
|
Germ-Line Mutation | 1 | 2015 | 1885 | 0.020 |
Why?
|
Health Services Needs and Demand | 1 | 2014 | 1406 | 0.020 |
Why?
|
Body Mass Index | 2 | 2014 | 13053 | 0.020 |
Why?
|
Linear Models | 1 | 2015 | 5884 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 2 | 2018 | 18065 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2014 | 6229 | 0.020 |
Why?
|
Guideline Adherence | 1 | 2015 | 2235 | 0.020 |
Why?
|
Qualitative Research | 1 | 2016 | 3140 | 0.010 |
Why?
|
Up-Regulation | 1 | 2013 | 4146 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2015 | 16045 | 0.010 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2014 | 1188 | 0.010 |
Why?
|
Boston | 1 | 2017 | 9374 | 0.010 |
Why?
|
Mutation | 2 | 2020 | 30238 | 0.010 |
Why?
|
Biopsy | 1 | 2015 | 6793 | 0.010 |
Why?
|
Genome, Human | 1 | 2016 | 4446 | 0.010 |
Why?
|
Social Support | 1 | 2013 | 2193 | 0.010 |
Why?
|
Body Weight | 1 | 2014 | 4627 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2013 | 3228 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2022 | 12795 | 0.010 |
Why?
|
Poverty | 1 | 2014 | 2720 | 0.010 |
Why?
|
Massachusetts | 1 | 2015 | 8890 | 0.010 |
Why?
|
Radiography | 1 | 2013 | 6983 | 0.010 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2013 | 1642 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2016 | 5341 | 0.010 |
Why?
|
Health Policy | 1 | 2013 | 2698 | 0.010 |
Why?
|
C-Reactive Protein | 1 | 2013 | 3858 | 0.010 |
Why?
|
Algorithms | 1 | 2021 | 14164 | 0.010 |
Why?
|
Sex Factors | 1 | 2014 | 10632 | 0.010 |
Why?
|
Registries | 1 | 2016 | 8375 | 0.010 |
Why?
|
Animals | 1 | 2011 | 169246 | 0.010 |
Why?
|
Adolescent | 2 | 2021 | 89169 | 0.010 |
Why?
|
Comorbidity | 1 | 2013 | 10590 | 0.010 |
Why?
|
Genotype | 1 | 2013 | 13045 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2011 | 12465 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2013 | 7454 | 0.010 |
Why?
|
Inflammation | 1 | 2013 | 10873 | 0.010 |
Why?
|
Child | 1 | 2021 | 80917 | 0.010 |
Why?
|
Cardiovascular Diseases | 1 | 2013 | 15662 | 0.000 |
Why?
|